- Adalimumab in juvenile rheumatoid arthritis/juvenile idiopathic arthritisKatherine Anne B Marzan
Childrens Hospital Los Angeles, 4650 Sunset Boulevard, MS 60, Los Angeles, CA 90027, USA
Expert Rev Clin Immunol 4:549-58. 2008..Anti-TNF agents are effective biologic modifiers that have had a major impact on the clinical course of arthritis. Adalimumab, a recombinant monoclonal antibody to TNF-alpha, is emerging as a valuable new therapy for juvenile arthritis...
- Early juvenile idiopathic arthritisKatherine Anne B Marzan
Division of Rheumatology, Children s Hospital Los Angeles, Keck School of Medicine of USC, 4650 Sunset Boulevard, MS 60, Los Angeles, CA 90027, USA
Rheum Dis Clin North Am 38:355-72. 2012..Control of disease activity within the first 6 months of onset confers improved clinical course and outcomes. The treatment perspective is thus one of early aggressive treatment for induction of disease control and ultimately remission...